Skip to main content

Table 1 Cox regression univariate analysis of variables for overall survival in AML patients

From: Comprehensive analysis of SPAG1 expression as a prognostic and predictive biomarker in acute myeloid leukemia by integrative bioinformatics and clinical validation

Variables

Whole-cohort AML

Non-M3 AML

CN-AML

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

SPAG1 expression

2.280 (1.562–3.327)

0.000

2.011 (1.366–2.962)

0.000

2.279 (1.283–4.047)

0.005

SPAG2/UAP1 expression

1.313 (0.908–1.897)

0.148

1.536 (1.052–2.241)

0.026

1.051 (0.614–1.798)

0.857

SPAG3/SPAG8 expression

0.901 (0.624–1.302)

0.578

1.021 (0.699–1.490)

0.914

0.801 (0.469–1.367)

0.416

SPAG4 expression

0.881 (0.610–1.273)

0.501

1.047 (0.718–1.527)

0.812

0.762 (0.442–1.315

0.329

SPAG5 expression

0.845 (0.584–1.223)

0.373

0.747 (0.509–1.096)

0.136

0.564 (0.319–0.998)

0.049

SPAG6 expression

1.504 (1.039–2.178)

0.031

1.359 (0.929–1.988)

0.114

0.990 (0.575–1.705)

0.971

SPAG7 expression

0.752 (0.519–1.089)

0.131

0.820 (0.560–1.202)

0.310

0.854 (0.498–1.467)

0.568

SPAG9 expression

0.986 (0.683–1.423)

0.939

0.906 (0.621–1.321)

0.607

1.176 (0.686–2.014)

0.556

SPAG10/MFGE8 expression

0.890 (0.616–1.287)

0.537

1.026 (0.703–1.498)

0.892

0.696 (0.406–1.193)

0.187

SPAG13/ITPRID2 expression

0.854 (0.591–1.234)

0.401

0.777 (0.532–1.134)

0.191

1.170 (0.683–2.004)

0.567

SPAG16 expression

1.427 (0.985–2.069)

0.060

1.257 (0.857–1.843)

0.242

1.320 (0.769–2.266)

0.314

SPAG17 expression

0.936 (0.648–1.351)

0.722

0.913 (0.626–1.332)

0.637

0.850 (0.498–1.453)

0.553

  1. AML: acute myeloid leukemia; CN-AML: cytogenetically normal AML; HR: hazard ratio; CI: confidence interval. The prognostic value of SPAG11A, SPAG11B, and SPAG16/SPAM1 expression was not determined because the three members were hardly expressed in AML patients